Download as pdf or txt
Download as pdf or txt
You are on page 1of 2

THE BOTTOM LINE

Neutropenic Diet – Good Practice or Myth?


Michael Boeckh

Hematopoietic cell transplant (HCT) is one of beneficial in a properly powered randomized trial in
the most complex procedures in medicine. Since its patients undergoing HCT with current transplanta-
inception several decades ago, it has been continu- tion practices.
ously refined and is now a standard procedure for In this issue of Biology of Blood and Marrow Trans-
many hematologic malignancies and some nonmalig- plantation, Trifilio et al. [4] report the results of a ret-
nant diseases. However, despite these advances, re- rospective analysis of outcomes in a cohort study of
lapse of the underlying disease, graft-versus-host 363 mainly autograft recipients who did not receive
disease (GVHD), organ toxicities, and infectious a strict neutropenic diet but rather a general hospital
complications continue to be major obstacles to suc- diet that mandated safe food handling practices but
cess. Inherent to the HCT procedure is a profound permitted black pepper and well-washed fresh fruits
posttransplantation immunodeficiency, which in- and vegetables (raw tomatoes, seeds, and grains
creases the risk of serious and often fatal infectious were excluded and other restrictions also remained
complications. Infections can originate from exoge- in place). Outcomes were compared with a well-
nous acquisition of pathogens or reactivation from matched historical cohort of the same size that re-
latency. Once infected, the patient may develop pro- ceived a standard strict neutropenic diet. The study
gressive and often fatal disease. Infections have also showed a higher rate of microbiologically confirmed
been implicated in the development of GVHD. To infections after resolution of neutropenia in patients
minimize exposure from food-borne pathogens, who received the strict neutropenic diet and similar
most cancer centers recommend a restricted diet. rates of diarrhea, gastrointestinal GVHD, days of
This diet, also referred to as the ‘‘neutropenic diet’’, hospitalization, and overall mortality. Although these
is usually recommended throughout the period of im- results are intriguing, the study has notable limita-
munosuppression with the goal to minimize invasive tions, including the primarily autologous transplan-
infections originating from food-derived pathogens tation population (which limits the ability to study
and, in the allogeneic transplantation setting, also to the effects on GVHD), the lack of accounting for
potentially minimize GVHD. The practice to recom- the degree of gut toxicity of the conditioning regi-
mend this diet is endorsed by evidence-based guide- mens, the low incidence of some infections (eg,
lines; however, the quality of the evidence is molds), the single-center experience, the lack of sta-
generally weak - mostly category III (ie, based on ex- tistical power for specific infections, and, most im-
pert opinion) [1,2]. In fact, although there are portantly, the nonrandomized nature of the study.
theoretical arguments as well as preclinical non- However, the results are provocative and should
human studies and clinical results from the early give us pause. Recent discoveries of the impact of
days of HCT [3] to support the concept, the strategy the gut microbiota on the immune system [5], bacte-
as a whole has never been evaluated and proven to be rial invasion [6,7], and GVHD [8] have provided new
insight into the pathogenesis and interrelationship of
gut pathogens, translocation, and inflammation and
From the Vaccine and Infectious Disease and Clinical Research suggest a far more complicated relationship between
Divisions, Fred Hutchinson Cancer Research Center, pathogens, the immune system, and clinical out-
Department of Medicine, University of Washington, Seattle, comes than previously assumed. We now have the
Washington. tools to study these interactions of gut pathogens
Financial disclosure: See Acknowledgments on page 1319.
in the context of diet after HCT. Not only was the
Correspondence and reprint requests: Michael Boeckh, MD, Fred
Hutchinson Cancer Research Center, 1100 Fairview Avenue neutropenic diet not beneficial in the analysis by
North, Seattle, WA 98109 (e-mail: mboeckh@fhcrc.org). Trifilio et al. [4], there was also a suggestion that
Received July 6, 2012; accepted July 6, 2012 it could potentially be harmful. In addition, the re-
Ó 2012 American Society for Blood and Marrow Transplantation strictions that go with neutropenic diet are often dis-
1083-8791/$36.00
liked by patients. Indeed, the authors report a clear
http://dx.doi.org/10.1016/j.bbmt.2012.07.006

1318
Biol Blood Marrow Transplant 18:1318-1321, 2012 The Bottom Line 1319

preference for the less restrictive diet among patients be platforms to conduct such trials and funding
who experienced both forms of diet during the tran- agencies should make it a priority to fund research
sition period at their center. Although this was not of the biologic effects of diet on outcomes in
a formal quality of life analysis, these preferences transplantation recipients and patients with cancer.
are plausible and future studies should include a -
formal analysis of how diet affects quality of life after
HCT.
Where should we go from here? The article by ACKNOWLEDGMENTS
Trifilio et al. [4], the generally weak or lacking clinical Financial disclosure: The author has no conflict of
evidence supporting current practices of recommend- interest to declare that is relevant to this topic.
ing strict neutropenic diets [1], and the results of re- Grant support: National Institutes of Health
cent randomized and nonrandomized pilot trials in HL093294.
patients with hematologic cancer [9,10] all call for
a renewed systematic look at the neutropenic diet in
HCT recipients. It would not be the first time that
REFERENCES
an intervention strategy made good theoretical sense,
but ultimately was ineffective when put to the test. 1. Yokoe D, Casper C, Dubberke E, et al. Safe living after hemato-
poietic cell transplantation. Bone Marrow Transplant. 2009;44:
Prospective cohort studies aimed at examining
509-519.
the impact of adherence to the neutropenic diet 2. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for prevent-
on the gut microbiome, the immune system, ing infectious complications among hematopoietic cell trans-
infectious complications, the development of plantation recipients: a global perspective. Biol Blood Marrow
Transplant. 2009;15:1143-1238.
GVHD, quality of life, and overall clinical outcome 3. Storb R, Prentice RL, Buckner CD, et al. Graft-versus-host
are needed to understand the biologic effects of the disease and survival in patients with aplastic anemia treated
neutropenic diet and its effect on clinical endpoints. by marrow grafts from HLA-identical siblings. Beneficial ef-
The results from these studies will inform the design fect of a protective environment. N Engl J Med. 1983;308:
302-307.
of randomized trials, which should ultimately be 4. Trifilio S, Helenowski I, Giel M, et al. Questioning the role of
performed. Two randomized trials in patients a neutropenic diet following hematopoetic stem cell trans-
with cancer who are undergoing chemotherapy plantation. Biol Blood Marrow Transplant. 2012;18:1387-1392.
are presently ongoing according to the www. 5. Jarchum I, Pamer EG. Regulation of innate and adaptive immu-
nity by the commensal microbiota. Curr Opin Immunol. 2011;23:
clinicaltrials.gov database (NCT00726934, NC- 353-360.
T00947648). The autologous transplantation setting 6. Taur Y, Xavier JB, Lipuma L, et al. Intestinal domination and
is an obvious first target for randomized trials and the risk of bacteremia in patients undergoing allogeneic hemato-
one might argue that the data now available are poietic stem cell transplantation. Clin Infect Dis. 2012 [Epub
ahead of print].
sufficient to propose such study provided appropriate 7. Stecher B, Hardt WD. Mechanisms controlling pathogen colo-
stopping rules are included in the design. In the nization of the gut. Curr Opin Microbiol. 2011;14:82-91.
allogeneic setting, a more cautious approach seems 8. Jenq RR, Ubeda C, Taur Y, et al. Regulation of intestinal inflam-
mation by microbiota following allogeneic bone marrow trans-
prudent due to the higher risk of serious invasive
plantation. J Exp Med. 2012;209:903-911.
infectious and the possible adverse effects on 9. Gardner A, Mattiuzzi G, Faderl S, et al. Randomized compari-
GVHD. Such trials are costly but are needed in son of cooked and noncooked diets in patients undergoing re-
order to replace expert opinion with actual data and, mission induction therapy for acute myeloid leukemia. J Clin
Oncol. 2008;26:5684-5688.
ultimately, improve outcomes and quality of life. 10. DeMille D, Deming P, Lupinacci P, Jacobs LA. The effect of the
Clinical trial organizations such as the Blood and neutropenic diet in the outpatient setting: a pilot study. Oncol
Marrow Transplant Clinical Trials Network could Nurs Forum. 2006;33:337-343.

You might also like